NEW YORK (GenomeWeb) — Transgenomic said after the close of the market on Wednesday that its second quarter revenues declined 7 percent year over year.

For the three months ended June 30, the Omaha, Neb.-based company reported $6.8 million in revenues compared to $7.3 million in the same quarter last year. Transgenomic said this decline was attributable to a $300,000 decrease in its Genetic Assays and Platforms segment due to fewer instrument sales, and a $200,000 drop in Laboratory Services revenues due to lower sales of contract development services to pharmaceutical clients.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Oct
02
Sponsored by
Roche

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.